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Abstract 
Insulin receptor (Insr) protein can be found at higher levels in pancreatic β-cells than in most other 
cell types, but the consequences of β-cell insulin resistance remain enigmatic. Ins1cre allele was used 
to delete Insr specifically in β-cells of both female and male mice which were compared to Ins1cre-
containing littermate controls at multiple ages and on multiple diets. RNA-seq of recombined β-cells 
revealed significant differences in multiple pathways previously implicated in insulin secretion and 
cellular fate, including rewired Ras and NFKB signaling. Male, but not female, βInsrKO mice had 
reduced oxygen consumption rate, while action potential and calcium oscillation frequencies were 
increased in Insr knockout β-cells from female, but not male mice. Female βInsrKO and βInsrHET mice 
exhibited elevated insulin release in perifusion experiments, during hyperglycemic clamps, and 
following i.p. glucose challenge. Deletion of Insr did not reduce β-cell mass up to 9 months of age, nor 
did it impair hyperglycemia-induced proliferation. Based on our data, we adapted a mathematical 
model to include β-cell insulin resistance, which predicted that β-cell Insr knockout would improve 
glucose tolerance depending on the degree of whole-body insulin resistance. Indeed, glucose 
tolerance was significantly improved in female βInsrKO and βInsrHET mice when compared to controls at 
9, 21 and 39 weeks. We did not observe improved glucose tolerance in adult male mice or in high fat 
diet-fed mice, corroborating the prediction that global insulin resistance obscures the effects of β-cell 
specific insulin resistance. We further validated our in vivo findings using the Ins1-CreERT transgenic 
line and found improved glucose tolerance 4 weeks after tamoxifen-mediated Insr deletion. 
Collectively, our data show that loss of β-cell Insr alone is sufficient to drive glucose-induced 





Type 2 diabetes is a multifactorial disease wherein several cell types, most prominently pancreatic 
β-cells, are dysfunctional prior to and after diagnosis (Prentki and Nolan, 2006). Hyperinsulinemia, 
insulin resistance, impaired fasting glucose, and impaired glucose tolerance can all be observed prior 
to the onset of frank diabetes (Tabak et al., 2012), but the causal relationships between these factors 
remain incompletely understood (Page and Johnson, 2018). Impaired insulin receptor signaling is 
associated with obesity and often precedes the onset of overt type 2 diabetes, but it has been studied 
primarily in skeletal muscle, fat, and liver where it manifests differently (Boucher et al., 2014). Recent 
work in mice has established that β-cell specific insulin resistance can be observed early in the 
progression towards type 2 diabetes, when hyperinsulinemia is prominent, and independently of 
insulin resistance in other tissues (Paschen et al., 2019). The physiological consequences of reduced 
insulin receptor (Insr)-mediated signaling in β-cells remain controversial. 
It remains unresolved whether physiological insulin action on β-cells manifests as positive feedback 
to stimulate further insulin secretion, or negative feedback to inhibit its own release (Leibiger et al., 
2008). Human studies provide evidence for both possibilities. In vivo hyperinsulinemic-euglycemic 
clamps have been shown to reduce circulating C-peptide, a marker of endogenous insulin secretion 
(Cavallo-Perin et al., 1993; Elahi et al., 1982). In some studies, this inhibition was impaired in the 
obese state suggesting that systemic insulin resistance also extends to the β-cells (Cavallo-Perin et 
al., 1993). Bouche and colleagues replicated this result at basal glucose, but also found evidence that 
insulin can potentiate glucose-stimulated insulin secretion under specific conditions (Bouche et al., 
2010). Others have shown that insulin can either stimulate or inhibit its own secretion depending on 
the metabolic context (Mari et al., 2011). Administration of insulin to single β-cells in vitro increases 
intracellular Ca2+ (Johnson and Misler, 2002a) and, in some studies, stimulates exocytosis (Aspinwall 
et al., 1999). However, Ca2+ release from intracellular stores is not always sufficient to evoke insulin 
exocytosis. We previously did not detect robust exocytosis or C-peptide release from human β-cells in 
response to exogenous insulin despite observed changes in Ca2+ release (Luciani and Johnson, 
2005). 
Whether chronic changes in autocrine insulin signaling affect β-cell development, survival and 
adaptation conditions is also controversial. Mice with chronically reduced insulin production have 
.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted October 15, 2020. ; https://doi.org/10.1101/2020.10.15.338160doi: bioRxiv preprint 
 
4
impaired β-cell expansion in the context of a high fat diet (Mehran et al., 2012). In vitro, physiologically 
relevant concentrations of insulin support the survival of both human and mouse β-cells (Johnson et 
al., 2006a). We also reported insulin is sufficient to increase proliferation of cultured primary mouse β-
cells and that blocking insulin secretion with somatostatin blunts proliferation induced by 
hyperglycemia in vitro (Beith et al., 2008) and that the majority of glucose-dependent changes in gene 
expression in MIN6 cells are Insr-dependent (Ohsugi et al., 2005). However, it has also been 
proposed hyperglycemia-induced β-cell proliferation bypasses the Insr (Jhala et al., 2003; Stamateris 
et al., 2016). Thus, whether these signals from insulin and/or glucose are transmitted through Insr, 
Igf1r, or both receptors, remains unresolved. 
To address the short- and long-term consequences of eliminating Insr signaling in vivo, Kulkarni 
and colleagues generated mice with a floxed Insr allele and an Ins2 promoter driven Cre transgene 
(Kulkarni et al., 1999). Using this and related models, they reported that mice lacking β-cell Insr have 
profound glucose intolerance, and frank diabetes in some cases, due to impaired glucose stimulated 
insulin secretion, Glut2 loss, and insufficient β-cell mass (Kulkarni et al., 1999; Okada et al., 2007; 
Otani et al., 2004). Mice lacking Insr in β-cells (and other off-target cell types) failed to exhibit the 
compensatory increase in β-cell mass that accompanies a high fat diet in mice (Okada et al., 2007). 
Doubt was cast on some of these results when these Cre lines were subsequently shown to have off-
target tissue effects owing to endogenous Ins2 expression in the brain and thymus (Fan et al., 2009; 
Johnson, 2014; Mehran et al., 2012; Wicksteed et al., 2010a). More recently, Wang and colleagues 
studied the roles of β-cell Insr in utero and in adult mice using an inducible Ins1-CreER transgenic 
mouse model (Oakie et al., 2020; Wang et al., 2018), but these studies are confounded by the 
presence of the human growth hormone (hGH) minigene (Oropeza et al., 2015), which necessitates 
the use of Cre-containing controls exclusively. 
In the present study, we used the constitutive Ins1Cre knock-in strain with robust and specific 
recombination in β-cells (Thorens et al., 2015) to precisely reduce insulin receptor signaling and define 
the impacts of β-cell specific insulin resistance on glucose homeostasis. Using this approach, we 
found that insulin receptor signaling plays a suppressive role on insulin secretion by modulating β-cell 




Insr abundance in human islets and β-cells  
We initiated our studies by conducting an unbiased analysis of insulin receptor abundance across 
tissues using publicly accessible data. Pancreatic islets had the 2nd highest protein abundance of both 
isoforms of the insulin receptor across a panel of 24 human tissues, as quantified by mass-
spectrometry (Fig. 1A). These results, which are not complicated by the limitations associated with 
anti-insr antibodies, show that islets have more INSR protein than ‘classical’ insulin target tissues, 
including the liver and adipose. This also supports our previous observations suggesting that insulin 
receptors are more abundant in β-cells relative to other cells in the pancreas (Boothe et al., 2016). 
Compilation of open source public single-cell RNA sequencing data from human islets demonstrated 
at least one count of insulin receptor mRNA in 62.4% β-cells, alongside other islet cell types (Fig. 
1A,B). 
 
β-cell specific Insr deletion with Ins1Cremice 
We next sought to examine the function of the Insr, and the consequences of β-cell-specific insulin 
resistance/sensitivity, using an in vivo β-cell specific knockout mouse model. To limit recombination of 
the floxed Insr allele to pancreatic β-cells, we used a Cre allele knocked into the endogenous Ins1 
locus which, unlike Ins2 promoters, drives specific expression in β-cells (Thorens et al., 2015). 
Experimental Insrf/f;Ins1cre/wt;nTnG (βInsrKO) and Insrf/wt;Ins1cre/wt;nTnG (βInsrHET) mice and littermate 
control Insrwt/wt;Ins1cre/wt;nTnG mice were generated using a breeding scheme to ensure consistency of 
the Cre donor parent (Fig. 1C). Cre-recombinase efficiency was assessed using the nuclear 
TdTomato-to-nuclear EGFP (nTnG) lineage trace reporter (Prigge et al., 2013) and found to be robust 
on the Insrf/f;Ins1cre/wt;nTnG genetic background (Fig 1D). We confirmed by Western blotting that Insr 
protein was almost completely absent from βInsrKO islets and partially reduced from βInsrHET (Fig. 1E). 
qPCR showed that Insr mRNA was not decreased in any of the 18 tissues examined, including the 
whole brain or hypothalamus specifically, hence we did not perform Western blots for other tissues 
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(Fig. 1F). Together with other published data on Ins1cre mice, these data strongly suggest that Insr 
deletion with Ins1cre is robust and sufficiently specific to pancreatic β-cells. 
 
Loss of β-cell Insr alters gene expression in purified β-cells  
To establish a baseline gene expression profile of our β-cell specific Insr knockout model we 
performed an unbiased global analysis of β-cell gene expression in FACS purified GFP-positive β-cells 
labelled with the nTnG reporter (Fig. S1A). RNA sequencing revealed significant differences in mRNA 
expression between βInsrKO β-cells and wild type β-cells (Fig. 2; Fig. S1B-E). Overall, differentially 
expressed genes were enriched in Reactome pathways related to NFκB signaling, Ras signaling, and 
mRNA splicing (Fig. S1B). In many cases, Insr gene deletion showed a gene-dose-dependent effect 
on regulated gene expression meaning that heterozygous βInsrHET β-cells exhibited intermediate 
expression of target genes between the full Insr knockout and wildtype β-cells (Fig. S1C). 
Significantly upregulated individual mRNAs in βInsrKO mice included genes that promote insulin 
secretion (Jak2, Atp6ap2), mediate cell death (Tmem123, Dusp26, Rela) and mitochondria 
fragmentation (Cers6), and repress β-cell maturity (Dusp26) and proliferation (Rela, Kras), or 
participate in islet development (Tm4sf4)(Anderson et al., 2011; Chamberlain et al., 2014; Dai et al., 
2015; Gomez-Banoy et al., 2019; Ma et al., 2001; Mandrup-Poulsen, 2003; Zhang et al., 2006). 
Several of the upregulated individual genes have been reported to be significantly associated with 
glycemic or obesity traits in human GWAS studies, including Utp3, Rela, Cers6, Rnf6, and Tbce (Fig. 
S1C; www.type2diabetesgenetics.org). Collectively, these upregulated genes point to β-cells that may 
be hyper-secretory, but are perhaps more susceptible to some stress conditions. 
Individual genes that were significantly decreased included regulators of β-cell function, including 
the regulation of KATP channels, and β-cell fate (Brsk2, Rab3a, Bmpr2, Camk2b, Mapk8ip3), a negative 
regulator of Glut2 protein abundance (Prnp), a regulator of endocytosis (Vps8), a mediator of 
autophagy and cellular cholesterol traffic (Gramd1a), an anti-apoptosis gene (Rel), a transducer of ER 
stress (Atf6b), and a histone methyltransferase and STAT target gene (Mettl8)(Ashok and Singh, 
2018; Engin et al., 2013; Fornoni et al., 2008; Frau et al., 2017; Goulley et al., 2007; Gu et al., 2018; 
Kline et al., 2013; Laraia et al., 2019; Locke et al., 2015; Mokhtari et al., 2009; Tobi et al., 2018; Wang 
et al., 2005; Yaekura et al., 2003; Yang et al., 2015; Zhang et al., 2001). Several of these 
downregulated genes showed strong evidence for genome-wide association with glycemic traits, 
including Ttll12, C2, Atf6b, Sympk, and Camk2b (Fig. S1C). Interestingly, Ddx31 is a genetic regulator 
of circulating proinsulin levels in women but not men (Strawbridge et al., 2011). Hnf4g belongs to a 
network of transcription factors that play essential roles in β-cell function and fate but its specific role is 
unclear (Hara et al., 2000). Together, analysis of upregulated and downregulated genes points to the 
possibility that β-cells lacking Insr may exhibit increased glucose-stimulated insulin secretion but 
increased susceptibility to stress.  
We also used unbiased protein-protein interaction network analysis to examine the relationships 
between the differentially expressed genes, as well as known components of the insulin signaling 
pathways. We identified key network hubs downstream of β-cell Insr (Fig. S1D). We also predicted the 
transcriptional regulators of Insr-regulated differentially expressed genes. Of these transcription 
factors Rel, Pygo2, Polr2a, Nanos1 were significantly decreased and Jak2, Thap3 significantly 
increased in Insr-deficient β-cells. These are likely to be the more proximal mediators of the Insr-
dependent transcriptional program in β-cells (Fig. S1E). 
 
Loss of β-cell Insr increases β-cell excitability  
The RNA-seq analysis of Insr-regulated genes implicated multiple factors known to promote insulin 
secretion, including regulators of Glut2, mitochondria, KATP channels, and granule trafficking. We did 
not observe significant differences in the intensity or gross localization of Glut2 protein using 
immunofluorescence imaging (Fig. 3A,B). We examined mitochondrial function using the Seahorse 
bioanalyzer and found no significant differences between groups in females. In males, we observed a 
significant reduced oxygen consumption rate in dispersed islets from both βInsrKO and βInsrHET in 
comparison to controls during basal respiration and after antimycin A/rotenone injections, suggesting 
reduced ATP production (Fig. 3C). Insulin administration has been reported to open β-cell KATP 
channels, mediating negative feedback on insulin secretion (Khan et al., 2001). Lack of this 
endogenous insulin action through Insr would therefore be expected to lead to β-cell hyper-excitability 
in our mouse model in the context of high glucose. Indeed, electrophysiological analysis of single β-
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cells from female βInsrKO mice confirmed a significant increase in action potential firing frequency 
during glucose stimulation, when compared to control β-cells, with no differences in resting potential, 
firing threshold, or action potential height (Fig. 3D,E). The reversal potential was right-shifted in βInsrKO 
β-cells, further suggesting reduced K+ conductance (Fig. 3G). Interestingly, the hyper-excitability was 
observed in Insr knockout β-cells from female, but not male mice (Fig. 3E,F). Perhaps the reduced 
mitochondrial efficiency in males prevented β-cell hyperexcitability. It is also possible that male control 
β-cells were already maximally insulin resistant when studied. No significant differences have been 
identified in Insr mRNA expression between sorted β-cells from female and male islets (Stancill et al., 
2019). We did not observe a statistically significant difference in depolarization induced exocytosis in 
single cells from either sex (Fig. 3H), suggesting that the late stages of insulin granule exocytosis are 
not altered under these conditions. 
Next, we analyzed Ca2+ responses to 15mM glucose in thousands of Fura-2-loaded dispersed islet 
cells and analyzed the data with an adaptation of our TraceCluster algorithm (Wills et al., 2016). In 
agreement with the electrophysiological data, Insr knockout β-cells from female mice exhibited a 
significantly greater number of oscillation peaks within the glucose stimulation period compared to 
control cells (Fig. 3I,J, S2). A similar increase in excitability was observed in βInsrHET β-cells. 
Collectively, these experiments demonstrate that β-cells lacking Insr have increased electrical activity, 
suggesting that insulin has a negative feedback influence on excitability in the context of 
hyperglycemia.  
 
Loss of β-cell Insr causes insulin hypersecretion in the context of stimulatory glucose 
Insulin secretion is driven by electrical excitability, so we next carefully examined the effects of 
partial and full β-cell Insr deletion on secretory function employing multiple orthogonal in vitro and in 
vivo assays. We used islet perifusion to examine the dynamics of insulin secretion ex vivo at rest (3 
mM glucose) and in response to 20mM glucose or 10mM glucose, as well as direct depolarization with 
30mM KCl. Islets from female 16 week-old βInsrKO and βInsrHET mice secreted more insulin in 
response to 20 mM glucose and 30 mM KCl compared to islets from control mice (Fig. 4A). No 
significant differences were observed at 3mM or 10mM glucose (Fig. 4A). Consistent with our 
electrophysiology data, we did not observe differences in islets from males of the same age and on 
the same diet (Fig. 4B). It seems possible that reduced ATP generation in male mice (Fig. 4C) offsets 
any enhanced excitability/Ca2+ responsiveness, to result in absence of significant changes in insulin 
secretion. 
This potentiation of high glucose-stimulated insulin secretion ex vivo in the complete and partial Insr 
knockout β-cells, led us to examine how insulin levels were affected by glucose stimulation in vivo 
using the hyperglycemic clamp technique in awake mice. For this cohort of mice, there were no 
significant differences in body mass (control 20.5 +/- 0.5g n=8 vs βInsrKO 20.8 +/- 0.4g n=10), lean 
mass (control 17.5 +/- 0.4g vs βInsrKO 17.3 +/- 0.2g), or fat mass (control 1.8 +/- 0.3g vs βInsrKO 2.2 +/- 
0.2g). Glucose infusion rates were adjusted in order to reach hyperglycemic levels (~19 mM) in 
βInsrKO and wild type control mice (Fig. 4C, D, G, H). Interestingly, slightly higher glucose infusion 
rates were necessary in female βInsrKO mice in comparison to control mice in order to reach similar 
hyperglycemic levels (Fig. 4C). In accordance with our ex vivo insulin secretion data, glucose-
stimulated insulin secretion was higher in female, but not in male βInsrKO mice compared with control 
mice (Fig. 4E, I). We further tested whether in vivo insulin secretion would be potentiated after a single 
bolus of glucose in mice with reduced β-cell Insr. At 11 weeks of age, plasma insulin response, 
relative to baseline, was significantly elevated 30 min after i.p. injection of 2g/kg body mass glucose in 
female, but not in male, βInsrKO mice compared to controls (Fig. 4K, L). In accordance with the 
electrophysiology, Ca2+ oscillation, and islet perifusion data, we detected no statistical difference 
between female genotypes in fasting plasma insulin in vivo at multiple ages (Fig. S3). Together, these 
experiments suggest that β-cell Insr can play suppressive role in glucose-stimulated insulin secretion 
without much impact on basal insulin secretion.  
 
Effects of β-cell Insr loss on insulin production, storage, processing and clearance 
 Insulin and insulin signaling can modulate protein synthesis in many cell types and we have 
previously provided evidence that soluble cellular insulin protein transiently increases in human islet 
cell cultures treated with exogenous insulin (Luciani and Johnson, 2005). To assess the quantitative 
contribution of Insr signaling to insulin production and mRNA translation rates we measured total islet 
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insulin content after acid-ethanol extraction and examined total protein synthesis rate using S35- 
methoioine/cysteine pulse labelling in isolated islets. Total insulin content and protein synthesis in 
isolated islets were unaffected by Insr deletion under these basal glucose conditions (Fig. 5M-P). 
To investigate the role of Insr signaling on β-cell stress and insulin clearance, we conducted 
analysis of plasma proinsulin to C-peptide ratios, and C-peptide to insulin ratios in the fasting state 
(4h) across multiple ages in both male and female mice, and on multiple diets (Fig. S4). While many of 
these parameters changed with age, no statistical differences between genotypes was seen in any of 
these parameters of mice fed either a low-fat diet (LFD) or a high fat diet (HFD). A trend towards lower 
insulin clearance was observed in LFD-fed female βInsrKO mice in comparison to wild type control 
mice at 7 weeks. Collectively, these experiments show that β-cell insulin receptor signaling has only a 
small, if any, effect on insulin processing and clearance at baseline glucose conditions. 
 
Beta-cell area and hyperglycemia-induced proliferation in mice lacking β-cell Insr 
As our RNA sequencing data revealed pathways downstream of Insr signaling that may affect β-cell 
proliferation capacity (Fig. 2), we examined baseline β-cell area and proliferation reserve capacity. 
Islet architecture and β-cell-to-α-cell ratio were not obviously perturbed (Fig. 5A). We did not detect 
significant differences associated with genotype in β-cell area in either female or male mice, at 13, 42 
weeks (LFD) or 54 weeks (HFD) of age (Fig. 5B). In comparison to control mice, HFD fed female 
βInsrKO mice had a tendency toward a smaller β-cell area at 54 weeks of age that were consistent with 
tendencies towards lower plasma insulin (Fig. S3C), proinsulin and C-peptide levels (Fig. S4). These 
data suggest that Insr may help support age-dependent β-cell expansion under some conditions. 
Prolonged hyperglycemia can stimulate β-cell proliferation in adult mouse β-cells (Sharma et al., 
2015), but whether this requires intact insulin receptor signaling remains controversial. To examine the 
role of Insr-mediated signaling on hyperglycemia-induced β-cell proliferation, we performed 4-day 
hyperglycemic infusions in βInsrKO and wild type control mice. In female mice, hyperglycemia (>10 
mM; Fig. 5F) resulted in mildly elevated insulin secretion in βInsrKO relative to control mice for the initial 
48 h, which was not sustained for the duration of the experiment (Fig. 5G,H), while glucagon levels 
declined similarly in both genotypes (Fig. 5I,J). There was no effect of Insr deletion on hyperglycemia-
induced proliferation of either β-cells or α-cells in females (Fig. 5K,L). In male mice, 96 h of 
hyperglycemia resulted in sustained hyperinsulinemia in βInsrKO mice (Fig. 5M-O), with no differences 
in circulating glucagon (Fig. 5P,Q). In male mice lacking β-cell Insr, this manipulation was associated 
with more β-cell proliferation (Fig. 5R,S). The fact that we did not observe a suppression of glucose-
induced proliferation of β-cells lacking Insr prompted us to determine the degree to which the broadly 
defined insulin signaling pathway was inhibited in our model. Indeed, glucose-induced Akt 
phosphorylation, shown by western blot of whole islet lysate, was statistically unaffected, and glucose-
induced Erk phosphorylation was only reduced ~50% in Insr knockout β-cells (Fig. 5T). It is likely that 
the Igf1r or a receptor tyrosine-kinase-independent mechanism initiates parts of intracellular post-
receptor ‘insulin signaling’ in the absence of Insr. Testing this hypothesis in the future will require truly 
β-cell specific double deletion of Insr and Igf1r.  
 
Modelling contributions of peripheral and β-cell specific insulin sensitivity to glucose homeostasis 
The continuum between insulin sensitivity and resistance impacts multiple tissues, including 
pancreatic β-cells. We observed that β-cell-specific insulin resistance resulted in insulin 
hypersecretion in the context of unchanged β-cell mass. We next used mathematical modelling to 
generate quantitative predictions of the dependence of glucose tolerance on both β-cell and whole-
body insulin resistance, both independently and synchronously. As described in the methods section, 
we modified the Topp model (Topp et al., 2000) to include insulin receptor-mediated negative 
feedback on insulin secretion, as indicated by our experimental data, with Sβ serving as the β-cell Insr-
specific insulin sensitivity parameter (see equations in Fig. 6A; for βInsrKO mice, Sβ = 0). Peripheral 
insulin sensitivity is represented by SP, (SI in the original Topp model). We used our hyperglycemic 
clamp data (Figs. 4C-H, S5A,B) to estimate Sβ in both female and male control mice and found Sβ,female 
to be significantly different from zero (Sβ,female = 3.4 +/- 1.5 nM-
1, p = 10-25) and significantly different 
from Sβ,male (p = 10
-24). Sβ,male was not significantly different from zero (Sβ,male = -0.05 +/- 1.0 nM
-1, p = 
0.7). In silico glucose tolerance tests found that decreased β-cell insulin-sensitivity (Sβ) (similar to 
βInsrKO mice) corresponded with elevated peak and plateau insulin secretion (Fig. 6B). As expected, 
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this was predicted to drive more rapid clearance of blood glucose (Fig 6C). Analysis of areas under 
the curve for glucose and insulin resulting from in silico glucose tolerance tests while varying SP and 
Sβ indicated that β-cell insulin resistance should have a marked effect on insulin secretion and glucose 
tolerance, most dramatically in conditions of low peripheral insulin sensitivity. Next, we compared the 
predictions of this model with experimental results. We used the in silico AUCGlucose values as a 
function of both SP and Sβ combined with averaged experimental AUGC values to estimate SP as a 
function of age for the low-fat diet conditions (Fig. S5C,D). We found that male values of SP for 
wildtype and mutant were indistinguishable from each other while females showed significant 
differences from each other and from the male values at all ages. As expected, HFD led to reduced 
peripheral insulin sensitivity (Fig. S5E). Collectively, these simulations show how β-cell insulin 
sensitivity and peripheral insulin sensitivity may combine to the regulation of glucose tolerance. 
 
Condition-dependent improved glucose tolerance with reduced β-cell Insr signaling 
To test our theoretical model experimentally, we examined glucose tolerance in female and male 
βInsrKO, βInsrHET, and control littermates at multiple ages between 4 and 52 weeks in the context of 
two diets. Significant improvements in glucose tolerance were observed in female mice with reduced 
Insr signaling at multiple ages, and in young males (Fig. 6F). Consistent with our mathematical 
modelling that suggested a diminished contribution of β-cell insulin resistance to glucose homeostasis 
in the context of greater whole-body insulin resistance, we did not observe significant effects of 
genotype in older male mice, or mice of either sex fed an insulin-resistance-inducing HFD (Fig. 6F). 
Thus, Insr deletion has little consequence on glucose tolerance in mice with already impaired pan-
tissue insulin resistance, which we and others have shown increases with age and is more 
pronounced in male mice (Fig. S5). 
The Ins1cre allele results in pre-natal gene deletion (Thorens et al., 2015). To assess the effects of 
Insr deletion in adult β-cells, and to determine the role of Insr on a different genetic background and 
under different housing conditions, we also phenotyped multiple cohorts of mice in which the Insrf/f 
allele was recombined by the Ins1 promoter-driven CreERT transgenic allele (commonly known as 
MIP-Cre) after injection with tamoxifen. In agreement with our observations in mice with constitutive 
loss of β-cell Insr, we found that glucose tolerance was significantly improved 4 weeks after β-cell-
specific Insr deletion in male mice (Fig. 6G). These differences were not maintained as the mice aged 
and presumably became more insulin resistant. In these mice, there were no significant differences 
observed in fasting glucose (control 4.8 +/- 0.3mM n=7 vs βInsrKO  4.4 +/- 0.2mM n=10), β-cell mass 
(control 1.4 +/- 0.3% n=3 vs βInsrKO 2.1 +/- 0.2% n=5), or body mass (control 26.1 +/- 1.1g n=7 vs 
βInsrKO 23.1 +/- 0.7g n=17. Collectively, these observations using an independent model and 
independent housing conditions lend support to our conclusion that the initial consequence of β-cell 
specific Insr deletion is improved glucose tolerance. 
 
Peripheral effects of β-cell specific Insr loss 
We and others have shown that even modest differences in hyperinsulinemia can have profound 
consequences for insulin sensitivity, adiposity, fatty liver, longevity and cancer (Mehran et al., 2012; 
Templeman et al., 2017; Zhang et al., 2019). Thus, we asked how the context-dependent glucose-
stimulated insulin hyper-secretion induced by targeted β-cell specific insulin resistance may affect 
insulin sensitivity, adiposity, and body mass over time. Insulin sensitivity was assessed at multiple 
ages in the same mice. Interestingly, insulin sensitivity was significantly improved in 10-week-old 
female βInsrHET mice compared to littermate controls without Insr deletion (Fig. S6). On a high fat diet, 
male βInsrKO and βInsrHET mice had significantly improved insulin sensitivity compared to controls at 22 
weeks of age. Longitudinal tracking of 4-h fasting glucose identified relative hypoglycemia in young 
LFD female βInsrKO and βInsrHET mice, older LDF male βInsrKO and βInsrHET mice, and across the 
tested ages in HDF female mice (Fig. 7A-D). Longitudinal tracking of body weight revealed that female 
mice with reduced β-cell Insr consistently weighed more than controls when fed a HFD (Fig. 7E-H), 
consistent with the known role of hyperinsulinemia in diet-induced obesity (Mehran et al., 2012; 
Templeman et al., 2015). We also examined the mass of several tissues at 13 weeks of age. 
Interestingly, liver mass was lower in both female and male mice lacking β-cell Insr (Fig. 7IJ). Pilot 
experiments showed that liver Insr protein abundance appeared reduced in mice with partially or 
completely reduced β-cell Insr, in the context of the LFD but not the HFD (Fig. 7K). These data are 
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consistent with the concept that modest hyperinsulinemia can drive down insulin receptor levels and 
the concept that insulin signaling is a trophic signal for liver. Together, these data demonstrate that 
specifically preventing autocrine insulin feedback can have systemic effects on insulin sensitivity, body 





The goal of the present study was to establish the role of β-cell specific insulin resistance on β-cell 
function and glucose homeostasis using specific genetic loss-of-function tools. We found that in vivo 
Insr deletion potentiated glucose-stimulated insulin secretion by increasing action potential firing and 
Ca2+ oscillation frequency, leading to improved glucose tolerance in insulin sensitive animals. Our data 
therefore suggest a model in which insulin inhibits its own secretion in a context-dependent manner 
and that this local negative feedback loop has physiological consequences for glucose tolerance. 
Autocrine signaling in endocrine cells is generally a negative feedback (Norman and Henry, 2014), 
with a few exceptions in specific conditions (Ma et al., 2005). Given the abundance of Insr protein in 
islets and the physiological modulation of both insulin and Insr signaling in health and disease, 
autocrine and paracrine insulin signaling have been topics of interest and controversy for decades 
(Braun et al., 2012; Leibiger et al., 2008). While some have questioned whether local insulin levels are 
sufficient for signaling within the islet, mathematical modelling of insulin hexamer dissolution estimated 
that monomeric insulin within islets is in the picomolar range (Wang et al., 2013), similar to the dose 
that maximally activates insulin signaling pathways (Alejandro et al., 2010; Beith et al., 2008). 
Consistent with a narrow range of responsiveness, our results also show that the contribution of 
autocrine insulin feedback to glucose homeostasis depends on whether mice are on a diet or at an 
age where insulin resistance is high, and potentially saturated in β-cells. Background genetics, diet, 
housing conditions, microbiome, or glucose concentrations could contribute to differences in observed 
phenotypes between our β-cell specific Insr knockout models and the frank diabetes reported for 
transgenic models that use fragments of the Ins2 or Pdx1 promoters to drive Cre-mediated β-cell insr 
deletion (Kulkarni et al., 1999; Okada et al., 2007; Otani et al., 2004). However, we believe that the 
discrepancy is more likely due to depletion of Insr in key neuronal populations since both of Ins2 and 
Pdx1 are expressed in brain regions that influence glucose homeostasis (Vogt and Bruning, 2013; 
Wicksteed et al., 2010a). For example, Insr deletion in the brain with Nestin Cre causes insulin 
resistance (Plum et al., 2005) and impairs the sympathoadrenal response to hypoglycemia (Fisher et 
al., 2005), while Insr knockout using AgRP Cre results in abnormal suppression of hepatic glucose 
production (Konner et al., 2007). We expect that our βInsrKO mouse line is the most tissue specific 
model used to date for the study of autocrine insulin signaling and β-cell insulin resistance. 
Using genetic and genomic tools, our work complements previous studies in humans and animal 
models. Ex vivo studies of perfused canine pancreata found an inhibitory autocrine effect of insulin 
(Iversen and Miles, 1971). Similarly, exogenous insulin perfusion of canine pancreas in situ was 
shown to lead to reduced endogenous insulin production (Rappaport et al., 1972). In vivo insulin 
infusion rapidly suppressed C-peptide levels in healthy men, but not those with obesity and 
presumably global insulin resistance (Cavallo-Perin et al., 1993). In isolated human islets, perifusion 
studies showed that treatment with physiological doses of insulin had no effect on C-peptide release 
(Johnson and Misler, 2002b), while static incubation experiments found only moderate potentiation of 
glucose-stimulated insulin secretion with super-physiological levels of insulin (Braun et al., 2012). Our 
conclusions are in line with the recent work of Paschen et al reporting that a high fat, high sucrose diet 
induced tissue-selective insulin resistance in β-cells, as well as profound hyperinsulinemia and β-cell 
hyper-excitability (Paschen et al., 2019). Our mechanistic finding that Insr knockout β-cells have 
increased action potential firing frequency is consistent with previous observations that insulin directly 
increased KATP currents via PI3-kinase signaling (Khan et al., 2001) and that PI3-kinase inhibition with 
wortmannin potentiates glucose stimulated insulin secretion in normal, but not T2D, human islets 
(Kolic et al., 2016). Our studies further illustrate the molecular mechanisms of negative autocrine 
feedback in β-cells during high glucose stimulation. 
Beyond the potentiation of glucose-stimulated insulin secretion, transcriptomic analysis of fully and 
partially Insr-deficient β-cells revealed a broad re-wiring of multiple signaling pathways and gene 
networks that are expected to change how these cells respond to stresses. In particular, Insr loss in 
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our model biased the combined insulin/Igf signaling pathway towards Ras/MAP-kinase signaling and 
increased in the capacity for cytokine signaling that could modulate cell fate. The conditions under 
which these gene expression changes could manifest in β-cell proliferation or increased β-cell survival 
remain incompletely explored. Otani et al reported modestly reduced β-cell mass in non-diabetic Ins2-
Cre transgenic Insr knockouts, which was exacerbated by diabetes, but they did not employ Cre 
controls (Otani et al., 2004). Okada et al reported impaired compensatory β-cell proliferation in the 
context of high fat diet or liver Insr knockout in the same experimental groups (Okada et al., 2007). 
These previous studies comparing β-cell knockout mice of Insr versus Igf1r, suggested a more 
important role for the former in β-cell proliferation and survival (Okada et al., 2007). Insulin receptor 
over-expression experiments also support the idea that β-cells are key insulin targets (Okamoto et al., 
2004). In the present study, we were unable to identify conditions which would result in statistically 
significant differences in β-cell mass in mice with Insr deficiency, but variability was high and relatively 
few animals were studied at older ages. We have previously shown that the increase in β-cell mass 
resulting from high fat diet requires local insulin production and is independent of hyperglycemia 
(Mehran et al., 2012), consistent with the known direct anti-apoptotic and mitogenic effects of insulin in 
vitro (Beith et al., 2008; Johnson et al., 2006a; Muller et al., 2006). These findings can be reconciled 
by proposing that high insulin concentrations within the islet are sufficient to activate remaining Igf1 
receptors linked to biased post-receptor signaling. We observed that sustained hyperglycemia and 
hyperinsulinemia over 4 days was associated with increased proliferation, but whether these are 
effects are mediated through Igf1r function compensation will require double receptor knockout 
experiments. It is also possible that hyperglycemia itself is a major driver of β-cell proliferation under 
these conditions, through Irs2-Creb signaling that may bypass Insr/Igf1r (Jhala et al., 2003). It has also 
been demonstrated that ~80% of the gene expression changes attributed to glucose in MIN6 cells 
require full insulin receptor expression (Ohsugi et al., 2005). We have previously found that glucose 
cannot stimulate primary mouse β-cell proliferation when autocrine insulin signaling is blocked by 
somatostatin and that ‘glucose-induced’ Erk phosphorylation requires full insulin secretion (Alejandro 
et al., 2010; Beith et al., 2008). On the other hand, inhibiting Insr in mouse islets with S961 or shRNA 
did not block glucose-induced proliferation of cultured β-cells (Stamateris et al., 2016). Additional 
future studies will be required to resolve this controversy. 
Early hyperinsulinemia is a feature of β-cell Insr knockout models on multiple genetic backgrounds 
(Kulkarni et al., 1999; Okada et al., 2007; Otani et al., 2004), including the present study. Loss of Irs1 
or Akt function results in basal hyperinsulinemia and, in some cases, increased β-cell mass (Bernal-
Mizrachi et al., 2004; Kido et al., 2000), mimicking the early stages in human diabetes. Our 
experiments begin to shed light on the systemic consequences of the hyperinsulinemia caused by β-
cell-specific insulin resistance, which may be an early event in the pathogenesis of type 2 diabetes. 
Human data  suggests that β-cell insulin resistance can be found in the obese state prior to 
hyperglycemia (Cavallo-Perin et al., 1993). We and others have shown that hyperinsulinemia 
contributes to insulin resistance and obesity (Mehran et al., 2012; Templeman et al., 2015), through 
multiple mechanisms including the down-regulation of insulin receptors (Knutson et al., 1983). We 
observed propensity for excessive diet-induced body mass gain in mice with β-cell specific insulin 
resistance, as well as Insr protein down-regulation in the liver. Thus, β-cell defects such as impaired 
autocrine feedback through Insr may contribute to insulin hypersecretion and accelerate the early 
stages of type 2 diabetes (Esser et al., 2020). In the later stages, the lack of pro-survival insulin 
signaling, perhaps in combination with other molecular defects, may contribute to failures in β-cell 
compensation and survival, thereby further accelerating the course of the disease (Gunton et al., 
2005; Kulkarni et al., 1999; Ohsugi et al., 2005; Okada et al., 2007; Otani et al., 2003).  
Our studies illustrate the power of using both females and males to study integrated physiology. 
Indeed, β-cell Insr loss led to increased β-cell action potentials, calcium oscillations, and glucose-
stimulated insulin secretion in 16-week-old female mice, but not in age-matched males. No intrinsic 
sex differences of Insr mRNA levels were in a transcriptomic analysis of sorted β-cells (Stancill et al, 
2019). Given the abundance of data showing more pronounced insulin resistance in males (Parks et 
al., 2015; Yki-Jarvinen, 1984), the most likely reason for these female-specific phenotypic responses 
to β-cell Insr deletion was the development of insulin resistance in control males but not in control 
females. To this point, glucose tolerance is improved in 4-week-old βInsrKO males, an age at which 
control males remain insulin-sensitive, and in male mice with acute loss of Insr. More work will be 
needed to confirm this possibility, and to determine factors in addition to sex hormones and sex 
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chromosomes that impact these sex differences in insulin sensitivity and glucose homeostasis 
(Mauvais-Jarvis, 2015). The sex-specific nature of phenotypes arising from our genetic manipulation 
of Insr in β-cells highlights the importance of including both sexes to accurately interpret data and to 
draw conclusions that will apply to both sexes. 
While our study is comprehensive and employs the best genetic tools available today, this work has 
limitations. Ins1Cre is the most β cell-specific Cre deletion strain available today (Thorens et al., 2015), 
but this fact does not preclude off-tissue effects that have yet to be discovered. Cre recombinase itself 
is not totally benign. These facts and our detailed comparison of Ins1wt/wt mice with Ins1Cre/wt mice 
(Figs. S7-10), highlight the importance of the Cre control group we employed throughout our studies. 
Recently, it was reported that some colonies of Ins1cre mice exhibited some silencing via DNA 
hypermethylation at the Ins1 locus and this was suggested as an explanation for discordance between 
the phenotypes compared to gene deletions using Pdx1-Cre and Ins2-Cre transgenic lines (Mosleh et 
al., 2020). In our study, we observed virtually complete recombination in β-cells and no evidence for 
off-tissue Insr deletion. We believe a major source of discrepancy with previously reported phenotypes 
stems from the propensity of previous promoter transgenic strains to recombine in the brain and 
robust expression of Insr throughout the brain. Another caveat of our experiments using βInsrKO mice 
is that Insr is expected to be deleted from β-cells starting in late fetal development (Thorens et al., 
2015). In our hands, tamoxifen-inducible Ins1CreERT mice have insufficient β-cell specific recombination 
for in vivo physiological studies. Our validation experiments using the tamoxifen-inducible Ins1-
CreERT address this limitation and confirm that β-cell insulin resistance improves glucose tolerance, 
at least under the initial insulin sensitive conditions. It should also be noted that, because we show 
that long-term deletion of Insr results in profound re-wiring of the β-cell transcriptome, the 
physiological changes can be the result of either direct or indirect action of Insr signaling. It should 
also be emphasized that, while we have deleted Insr, insulin can signal through Igf1r and Igf2r, 
especially at the higher concentrations predicted in the pancreas. A further caveat is that the 
molecular mechanisms involved in insulin secretion may be different in mouse and human β-cells 
(Rorsman and Ashcroft, 2018), although we note that direction of effect we surmise agrees with the 
majority of human and canine studies, indicating general agreement across species (Cavallo-Perin et 
al., 1993; Elahi et al., 1982; Iversen and Miles, 1971; Rappaport et al., 1972). 
In conclusion, our work demonstrates a key modulatory role for autocrine insulin negative feedback 
and the lack thereof (i.e. β-cell resistance) in insulin secretion, glucose homeostasis and body mass, 
which depend on the physiological context studied. We hope our studies resolved longstanding and 
controversial questions about the local effect of insulin on β-cells, and lead to experimental and 
theoretical studies that incorporate Insr-mediated signaling in other islet cell types. 
 
 
Materials and Methods 
Bioinformatics  
Human tissue-level proteome and transcriptome were downloaded from the ProteomicsDB 
resource (https://www.proteomicsdb.org)(Schmidt et al., 2018) in 2019 and sorted by relative protein 
abundance in Microsoft Excel. Publicly available human islet scRNAseq data were acquired from the 
panc8.SeuratData package and the SCTransform pipeline was followed to integrate the studies 
(Hafemeister and Satija, 2019). Expression data were normalized using the Seurat::NormalizeData 
function with default parameters and visualized using the Seurat::RidgePlot and Seurat::UMAPPlot 
functions, all from the Seurat package in R (Stuart et al., 2019). 
 
Mouse model and husbandry 
All animal protocols were approved by the University of British Columbia Animal Care Committee 
(Protocol A16-0022), the Institutional Animal Care and Use Committee of the University of 
Massachusetts Medical School (A-1991-17) and the University of Michigan Institutional Animal Care 
and use Committee, in accordance with national and international guidelines. Mice were housed at 
room temperature on a 12/12 light dark cycle at the UBC Modified Barrier Facility, unless otherwise 
indicated. 
 Ins1cre mice were gifted to us by Jorge Ferrer (Thorens et al., 2015) (now commercially available, 
Jax #026801). The Insrf/f allele (#006955) and the nuclear TdTomato-to-nuclear EGFP (nTnG) lineage 
tracing allele (Prigge et al., 2013) were obtained from Jax (#023035) (Bar Harbor, ME). We generated 
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two parental strains to avoid Cre effects during pregnancy; Ins1cre/wt;Insrf/wt male mice and 
Ins1cre/wt;nTnG/+ female mice. These two parental strains were crossed in order to generate full 
littermate insulin receptor knockout Insrf/f;Ins1cre/wt;nTnG/- (βInsrKO) mice, partial insulin receptor 
knockout Insrf/wt;Ins1cre/wt;nTnG/- mice mice (βInsrHET), and their control groups Insrwt/wt;Ins1cre/wt;nTnG/- 
mice (3 alleles of insulin) and Insrf/f;Ins1wt/wt;nTnG/- mice (4 alleles of insulin). Insrf, Ins1cre, and nTnG 
genotyping were done in accordance with Jax’s recommendations using a ProFlex PCR system 
(Thermo Fisher Scientific, Canada). NNT genotyping was done as described previously (Nicholson et 
al., 2010). Master mix for genotyping included 0.5μM primers (Integrated DNA technologies), 2mM 
dNTPs (New England Biolabs, #N0447S), 0.5U DreamTaq DNA polymerase (Fisher Scientific, 
#FEREP0702). Agarose gels varied from 1-2.5% (FroggaBio, #A87-500G). 
In our studies, mice were fed 1 of 3 diets: either a chow diet (PicoLab Mouse Diet 20-5058); a low-
fat diet (LFD; Research Diets D12450B) containing 20% of kcal protein, 10% of kcal fat, and 70% of 
kcal carbohydrate including 35% sucrose, or; a high-fat diet (HFD; Research Diets D12492) containing 
20% of kcal protein, 60% of kcal fat, and 20% of kcal carbohydrate including 10% sucrose. 
MIPcre mice were generously obtained from Dr Dempsey (Wicksteed et al., 2010b). The CAG-YFP 
reporter transgenic animals were from Jax (#011107). All animals were males that were 
intraperitoneally injected at 8 weeks of age for 5 consecutive days with tamoxifen (Sigma, T5648) 
freshly dissolved in corn oil (Sigma, C8267) with 3 injections at 200 mg/kg over a 1-week period. 
 
Comparison of control genotypes  
Before conducting our main study, we did a pilot experiment to determine whether the Ins1cre 
knock-in mice had any phenotype on their own under both low fat and high fat diets, and we tracked 
both ‘control’ genotypes for the majority of our studies. Although Insrwt/wt;Ins1cre/wt;nTnG and 
Insrf/f;Ins1wt/wt:nTnG control mice exhibited generally similar phenotypes, we observed key differences 
that reinforced the rationale for using controls containing Cre and lacking 1 allele of Ins1, matching the 
experimental genotypes. For example, male HFD-fed Insrf/f;Ins1wt/wt;nTnG mice showed significantly 
higher levels of plasma proinsulin in comparison to Insrwt/wt;Ins1cre/wt;nTnG mice at 16 and 28 weeks of 
age (Fig. S7). At several ages, both LFD and HFD fed female Insrf/f;Ins1wt/wt;nTnG/- mice exhibited 
trends toward slightly improved glucose tolerance (Fig. S8), most likely due to one extra allele of 
insulin, in comparison to Insrwt/wt;Ins1cre/wt;nTnG mice. Insulin sensitivity was generally similar, although 
not identical (Fig. S9). Longitudinal tracking of body weight revealed a consistent tendency for mice 
with a full complement of insulin gene alleles to be heavier than mice in which 1 allele of Ins1 had 
been replaced with Cre. With the statistical power we had available, female HFD-fed 
Insrf/f;Ins1wt/wt;nTnG mice had significantly increased body mass at 11 and 16 weeks of age in 
comparison to Insrwt/wt;Ins1cre/wt;nTnG mice (Fig. S10). Once we had established the effects of the 
Ins1cre allele on its own, we used a breeding strategy ensuring that all pups were born with 3 insulin 
alleles to control for any effects of reduced insulin gene dosage (See Fig. 1C). This strategy gave us 
cohorts of: Insrwt/wt;Ins1cre/wt;nTnG/- (βInsrKO) control mice, Insrf/wt;Ins1cre/wt;nTnG/- (βInsrKO) β-cell specific 
Insr heterozygous knockout mice, and Insrf/f;Ins1cre/wt;nTnG/- (βInsrKO) β-cell specific Insr complete 
knockout mice. In some studies, the nTnG allele was not present (see Figure legends).  
 
Islet isolation and dispersion 
Mouse islet isolations were conducted by ductal inflation and incubation with collagenase, followed 
by filtration and hand-picking as in our previous studies and following a protocol adapted from 
Salvalaggio et al. (Beith et al., 2008; Johnson et al., 2006a; Luciani and Johnson, 2005; Salvalaggio et 
al., 2002). 24h post islets isolations, islets were washed (x4) (Ca/Mg-Free Minimal Essential Medium 
for suspension cultures, Cellgro #15-015-CV), followed by gentle trypsinization (0.01%), and 
resuspended in RPMI 1640 (Thermo Fisher Scientific #11875-093), 10%FBS, 1%PS). Seeding were 




50 islets per sample were washed in PBS twice and then lysed and sonicated in RIPA buffer 
(10mM HEPES, 50mM β-glycerol phosphate, 1% Triton X-100) supplemented with complete mini 
protease inhibitor cocktail (Roche, Laval, QC) and phosphatase inhibitors (2mM EGTA, 70mM NaCl, 
347 1mM Na3VO4, and 1mM NaF). Protein concentration was measured using Micro BCA Protein 
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Assay Kit  (ThermoFischer Scientific). 10 μg of total protein for each sample was separated by SDS-
PAGE and transferred to Immun-Blot PVDF membrane (Bio-Rad Laboratories). Subsequently, 
membranes were blocked in I-Block (ThermoFischer Scientific) and probed with primary antibodies 
targeting insr-β subunit (1:1000, CST #3020S), ERK1/2 (1:1000, CST #4695), p-ERK1/2 
(Thr202/Tyr204) (1:1000, CST #4370), AKT (1:1000, CST #9272), p-AKT (Thr308) (1:1000, CST 
#9275), ACTB (Novus Biologicals, NB600-501). Protein detection was performed by the use of the 
HRP-conjugated secondary antibodies: anti-rabbit (CST #7074) or anti-mouse (CST #7076) and 
Immobilon Forte Western HRP substrate (Millipore Sigma). Protein band intensity on exposed film was 
measured with Adobe Photoshop software.  
 
Targeted gene expression analysis  
Tissue samples were kept frozen during grinding using mortals and pestles. cDNA was synthesized 
using qScriptTM cDNA synthesis kits (QuantaBio, #95047-500) following RNA was isolated from 50-
100mg of sample using RNeasy mini kits (Qiagen, #74106) according to manufacturer’s 
recommendations.  qPCR was performed in 15ul reaction volumes using a CFX384 Touch Real-Time 
PCR Detection System (BioRad). Primer sequences: Insr forward 5’- 376 
TTTGTCATGGATGGAGGCTA-3’ and Insr reverse 5’-CCTCATCTTGGGGTTGAACT-3’. Hprt forward 
5’-TCAGTCAACGGGGGACATAAA-3’ and hprt reverse 5’-GGGGCTGT 379 ACTGCTTAACCAG-3’. 
Insr expression data were analyzed using the 2-ΔΔCT method using Hprt as a housekeeping gene. 
∆Cq=Cq(Insr)-Cq(Hprt) followed by normalization of the ∆Cq(exp) to the mean of the Hprt expression 
in liver.  
 
RNA sequencing 
To generate transcriptomic data from β-cells lacking Insr and littermate controls, groups of 50 islets 
were dispersed using mild trypsin digest according to our standard protocol (Alejandro et al., 2010; 
Luciani and Johnson, 2005), and FACS purified based on the GFP-positivity of the Ins1Cre-induced 
nTnG allele. RNA isolation and library preparation were conducted in accordance with the SMART seq 
2 protocol (Picelli et al., 2014). Sequencing of 100 GFP-positive β-cells was performed at the UBC 
Sequencing and Bioinformatics Consortium using Illumina NextSeq 500 with paired-end 75 bp reads. 
The number of read pairs per sample ranged from 4 millions to 42 millions with a median of 18 
millions. Multiple analysis pipelines have been applied and their results combined using the procedure 
described elsewhere (Wang et al., 2019). One sample with exceptionally high glucagon reads was 
omitted, as a presumed β-cell purification failure. Pathway enrichment analyses were generated using 
Reactome and protein-protein interaction networks and subnetworks were derived using 
NetworkAnalyst 3.0 (http://www.networkanalyst.ca/)(Zhou et al., 2019). 
Protein-protein interaction network, sub-network and TF-gene network was generated from 
differentially expressed genes between KO and WT control group using Network Analyst 3.0 platform 
(http://www.networkanalyst.ca/)(Zhou et al., 2019). PPI network data were based on STRING 
interactome with high (900-1000) confidence score. PPI sub-network enriching KEGG ‘Insulin 
signaling pathway’ was generated using the Module Extraction function. TF-gene network data were 
based on ENCODE ChIP-seq data. 
 
Islet metabolism and oxygen consumption analysis 
The Seahorse XF Cell Mito Stress Test kit (cat#103015-100) was used to measure oxygen 
consumption rate (OCR) in dispersed mouse islets using an Agilent Seahorse XF96 Analyzer XF96 
(Seahorse Bioscience, North Billerica, MA). Dispersed islet cells were seeded at a density of 40,000 
cells/well. 48h post seeding, additionally, 180μL of Seahorse XF Calibrant Solution (cat#100840-000) 
was added to each well of the Seahorse XF Sensor Cartridge to hydrate the XF Utility Plate 
(cat#102416-100). The hydrated cartridge was kept in a non-CO2 incubator at 37Co for 24h hereby 
removing the CO2 from media. To allow the assay media to pre-equilibrate, 180 μL of assay (eagle's 
minimal essential medium (DMEM, no glucose, Gibco, (cat#103334-100) supplemented with 25 × 
10−3M glucose and 25 × 10−3M 4‐(2‐hydroxyethyl) ‐1‐piperazinemethanesulfonic acid(HEPES)) was 
added to each well 1 h prior to the run and used for extracellular flux measurements ofXF.  The plate 
was kept at 37 Co in a non-CO2 incubator. Mitochondrial respiration was analyzed by sequential 
injections of modulators including oligomycin (1M) used to block ATP synthase, carbonyl-cyanide-4-
(trifluoromethoxy) phenylhydrazone (FCCP 2.5M) to activate uncoupling of inner mitochondrial 
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membrane allowing maximum electron flux through the electron transport chain, and a mix of rotenone 
(1M) and antimycin A (1M) were used together to inhibit complexes I and III, respectively. The 
modulators were diluted in XF Assay Medium and loaded into the injection ports of the hydrated 
sensor cartridge corresponding to the order of injection 1 h prior to the run. 
 
Patch-clamp electrophysiology 
Islets from 16-week-old chow-fed male and female mice were isolated at UBC. 100-300 islets from 
each mouse shipped in a blinded manner overnight to the University of Alberta in RPMI (Invitrogen, 
11875) with 10% FBS (Invitrogen #12483020), and 1% penicillin-streptomycin (Thermo Fisher, 
#15070063). Islets were dissociated into single cells using StemPro accutase (Thermo Fisher 
Scientific, Cat# A11105-01) one day after receiving the islets. Dispersed cells were cultured in RPMI-
1640 containing 11.1 mM glucose with 10% FBS and 100 U/ml penicillin/streptomycin for up to 2 days. 
Membrane potential and current measurements were collected using a HEKA EPC10 amplifier and 
PatchMaster Software (HEKA Instruments Inc, Lambrecht/Pfalz, Germany) in either the current- or 
voltage-clamp mode in the perforated patch-clamp configuration. All the measures were done in a 
heated chamber (32–35°C). Membrane potential measurement was performed with patch pipettes 
pulled from thick-walled borosilicate glass tubes (Sutter Instrument), with resistances of 8–10 MΩ 
when filled with 76 mM K2SO4, 10 mM KCl, 10 mM NaCl, 1 mM MgCl2 and 5 mM Hepes (pH 7.25 with 
KOH), and back-filled with 0.24 mg/ml amphotericin B (Sigma, cat# a9528). The extracellular solution 
consisted of 140 mM NaCl, 3.6 mM KCl, 1.5 mM CaCl2, 0.5 mM MgSO4, 10 mM Hepes, 0.5 
mM NaH2PO4, 5 mM NaHCO3, 5 mM glucose (pH 7.3 with NaOH). Membrane potential was measured 
with 5 mM G starting from the beginning, for 5 min, then changed to 1 mM G for 4-5 min, then 
changed to 10 mM G for 8-10 min, finally changed back to 5 mM G. KATP currents and reversal 
potential were recorded during and after membrane potential measurement on each cell. β-cells were 
distinguished by characteristic differences in the voltage-dependent inactivation of Na+ channel 
currents (Gopel et al., 2000). 
Measurement of voltage-dependent exocytosis was performed in the whole-cell configuration. 
Before the start of whole-cell patch clamping, media were changed to bath solution containing (in 
mM): 118 NaCl, 20 Tetraethylammonium-Cl, 5.6 KCl, 1.2 MgCl2, 2.6 CaCl2, 5 HEPES, and 5 glucose 
(pH 7.4 with NaOH). For whole-cell patch-clamping, fire polished thin-walled borosilicate pipettes 
coated with Sylgard (3-5 MOhm), contained an intracellular solution with (in mM): 125 Cs-glutamate, 
10 CsCl, 10 NaCl, 1 MgCl2, 0.05 EGTA, 5 HEPES, 0.1 cAMP, and 3 MgATP (pH 7.15 with CsOH). 
Quality control was assessed by the stability of seal (>10 GOhm) and access resistance (<15 MOhm) 
over the course of the experiment. Data were analysed using FitMaster (HEKA Instruments Inc) and 
Prism 6.0h (GraphPad Software Inc., San Diego, CA).  
 
Calcium imaging and analysis 
Two days following cell seeding on glass coverslips, adherent islet cells were loaded with 5μM of 
the acetoxymethyl (AM) ester form of the calcium indicator Fura-2 (Thermo Fisher Scientific #F1221) 
for 30min. Islet cells were perifused at 1mL/min for 45min prior to experimental procedure to ensure 
washout of excess FURA2. During experiments, cells were mounted on a temperature-controlled 
stage and held at 37°C on a Zeiss Axiovert 200M inverted microscope equipped with a FLUAR 20× 
objective (Carl Zeiss,Thornwood, NY), while perifused with Krebs-Ringer (KRB) solution (144mM 
NaCl, 5.5mM KCL, 1mM MgCl2, 2mM CaCl2, 20mM HEPES) of various glucose concentrations as 
indicated in figures.  
Ca2+ traces were analyzed automatically, as follows. Taking a similar approach to that described 
previously (Wills et al., 2016), 8 features were extracted from the Traces (Fig S2). Peaks during each 
phase were identified as local maxima reaching a value with a percent difference above the median 
baseline level greater than 20%. P-values for calcium analysis were generated using ANOVA with 
correction for multiple comparisons performed using Tukey's method. Figures were generated 
using the ggplot2 package in R (Wickham2016). Code used to analyze data and generate figures are 
available upon request.  
 
Analysis of total protein synthesis rate 
For the purpose of pulse labeling of newly translated proteins, 50 isolated islets were incubated in 
complete RPMI media without cysteine and methionine (MP Biomedicals, #SKU 091646454) for 1hr. 
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Subsequently media was supplemented with 250 μCi of [35S]-cysteine/methionine mixture 
(PerkinElmer, NEG772002MC) and islets were incubated under normal conditions for 30 min. Islets 
were then lysed and proteins separated by SDS-gel electrophoresis as described above. Gels were 
fixed for 30 min in 50% (v/v) ethanol in water with 10% (v/v) acetic acid, dried in gel dryer (Bio-Rad 
model 583) and then exposed to storage phosphor screen (GE Healthcare) overnight. Screens were 
imaged and digitised using Typhoon FLA 9000 biomolecular imager (GE Healthcare). Protein bands 
intensity was quantified with Adobe Photoshop software. 
 
Dynamic insulin secretion perifusion analysis 
For perifusion experiments, islets from 16week old chow-fed male and female mice were isolated 
using collagenase, filtration and hand-picking as previously described (Johnson et al., 2006b). Our 
standard approach compared the insulin response to both 20mM and 10mM glucose stimulation as 
well as direct depolarization with 30 mM KCl. More specifically, 150 hand-picked islets per column 
were perifused (0.4 mL/min) with 3 mM glucose KRB solution containing (in mM) 129 NaCl, 4.8KCL, 
1.2 MgSO4•7H2O, 1.2 KH2PO4, 2.5 CaCl2, NaHCO3, 10 HEPES, as well as 0.5% BSA (Sigma # 
A7030) for 60 min to equilibrate the islets to the KRB and flow rate, and then treated as indicated. 
Samples were analyzed using a rat insulin radioimmunoassay that has 100% cross-reactivity for 
mouse insulin (Millipore-Sigma #ri-13k). Insulin content was measured after acid-ethanol extraction 
using an insulin ELISA (Stellux Rodent Insulin ELISA, Alpco #80-INSMR-CH10). 
 
Hyperglycemic clamps 
In vivo hyperglycemic clamp experiments were performed at the National Mouse Metabolic 
Phenotyping Center (MMPC) at UMass Medical School. Body composition analysis was conducted by 
noninvasively measuring whole body fat mass and lean mass using 1H-MRS (Echo Medical Systems, 
Houston, TX). A survival surgery was performed at 5–6 days before hyperglycemic clamp experiments 
to establish an indwelling catheter in the jugular vein. On the day of experiment, mice were fasted 
overnight (~15h), and a 2-h hyperglycemic clamp was conducted in awake mice by intravenously 
infusing 20% dextrose to rapidly raise and maintain plasma glucose levels at ~19 mM (Zhang et al., 
2012). 
 
Intravenous 4-day glucose infusion 
Mice were bred and genotyped at University of British Columbia and shipped at 5 weeks of age to 
the Division of Diabetes, Department of Medicine, University of Massachusetts Medical School, USA. 
In a blinded manner, glucose infusions were performed as described (Alonso et al., 2007). Jugular 
vein catheters were placed in 9-12-week-old male and female mice with blinded genotypes. From 
postoperative recovery through euthanasia mice were unrestrained and were maintained on a 12-h 
light/dark cycle, with access to 2.2 g diet (to ensure isocaloric intake across all mice) and water. After 
2 days of recovery, mice received continuous 4-day intravenous infusions of 50% dextrose (Baxter) 
containing 500ug/mL BrdU. Tail blood was sampled for plasma insulin, glucagon and blood glucose at 
Day 0, 1, 2 and 4. Blood glucose was measured using ReliOn glucometer (Walmart), glucagon was 
measured using mouse Glucagon ELISA (Mercodia 10-1281-01), and plasma insulin was measured 
using mouse Insulin ELISA kit (Mercodia 10-1247-01). Mice were euthanized at the end of the 
experiment and pancreas and duodenum were harvested for histology. Tissues were fixed for 5 h in 
10% formalin and then stored in 1X PBS until processing, paraffin embedding and sectioning. Images 
were acquired using a NIKON fully motorized for Phase and Fluorescence Ti-E microscope. Images 
were taken of at least 10 randomly selected islets, all four channels at the same time. To generate 
RGB images, channels were inserted to show Insulin-BrdU-DAPI, Glucagon-BrdU-DAPI or Insulin-
Glucagon-DAPI. To generate yellow-magenta-white images to accommodate colorblind viewers, new 
files were generated in Adobe Photoshop in which original channel data were displayed in multiple 
channels using the merge function (e.g. to change green to yellow, green channel data were added to 
both green and red channels; for more detailed information please contact LCA). Cells were counted 
using Cell profiler automated counting software from Broad Institute (Cambridge, MA); all counts were 
manually checked.  
   
β-Cell Mass and immunohistochemistry 
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Pancreata were perfused, then fixed for 24h with 4% paraformaldehyde, and then washed twice 
with 70% ethanol prior to paraffin embedding and sectioning (5 μm) to obtain 5 different regions of the 
pancreas (100 μm apart) by WAXit Inc. (Vancouver, Canada). Paraffin was removed by 5 min xylene 
incubation steps. Sections were rehydrated in decreasing concentrations of ethanol and rinsed with 
water and PBS. Epitope retrieval was done either by immersing samples 10 mM citrate buffer, pH 6.0 
for 15min at 95oC, or by transferring sections to prewarmed 1N HCl for 25 min at 37oC. Samples were 
washed with PBS twice and were either blocked for 10 min at room temperature (Dako protein block 
#X0909), or with goat block (GB) with Triton X-100 (10% BSA + 5% Goat Serum with 0.5% Triton X-
100) for 1-4 h at room temperature. Samples were incubated overnight at 4oC in primary antibodies 
targeting anti-insulin (1:200 Abcam #Ab7872), anti-glucagon (1:100 Cell Signaling Technologies, 
#2760S), anti-BrdU (1:250, Abcam ab6326), anti-GLUT2 (1:1000, Milipore, #07-1402). Following 3 
PBS washes (5 min each), samples were incubated for 30min or 1h at room temperature in secondary 
antibodies in a light-deprived humid chamber. Secondary antibodies applied were anti-rabbit Alexa 
Fluor-488 (1:200, Invitrogen, # A-11008), anti-rabbit Alexa-488 (1:200, Invitrogen, #A11034), anti-rat 
Alexa-594 (1:200, Invitrogen, #A11007), anti-guinea pig Alexa-647 (1:200, Invitrogen, #A21450), anti-
guinea pig Alexa-594 (1:200, Invitrogen #A-11076). Samples were mounted with either 
VECTASHIELD Hard Set Mounting Medium (Vector labs, # H-1500) or Fluoroshield both containing 
DAPI (Sigma-Aldrich, #F6182-20ML) following an additional three washes in PBS (10 min each). For 
β-cell area quantification, whole pancreas sections were imaged using an ImageXpressMICRO using a 
10x (NA 0.3) objective and analyzed using the MetaXpress software (Molecular Devices, San Jose, 
CA, USA). Beta cell area was calculated as insulin positive area normalized to the entire pancreas of 
each section. The mean of five sections from 5 regions of the pancreas were quantified. For other 
immunofluorescence analysis of fixed tissue, we used a Zeiss 200M microscope using 20x air 
objective (NA 0.75), NIKON fully motorized for Phase and Fluorescence Ti-E microscope. For live cell 
imaging for recombination validation, islets from Ins1cre/wt:nTnG mice were incubated with CellMask™ 
Deep Red Plasma membrane stain (Invitrogen/Thermo Fisher - Catalog number: C10046) using a 
Leica confocal microscope.  
 
Blood collection and in vivo analysis of glucose homeostasis and insulin secretion  
Tail blood was collected for blood glucose measurements using a glucometer (OneTouch Ultra 2 
meter, Lifescan, Canada) for single time points as well as during glucose and insulin tolerance tests. 
Mice were fasted for 4h or 16h during single timepoints and for 6h during glucose and insulin tolerance 
tests, as well as glucose stimulated insulin secretion tests. The i.p. glucose dose was 2g/kg unless 
otherwise specified. The i.p. Humalog (Eli Lilly and Co) insulin dose was 0.75U unless otherwise 
indicated. 1-2 days prior to femoral blood collection the experimental mice were tube handled and 
shaved. Femoral blood was collected for single timepoints, as well as for measurements of in vivo 
glucose-stimulated insulin secretion after i.p. injection of 2g/kg glucose. Blood samples were kept on 
ice during collection, centrifuged at 2000rpm for 10min at 4oC and stored as plasma at -20oC.  Plasma 
samples were analysed for insulin (Stellux Chemi Rodent Insulin ELISA, Alpco #80-INSMR-CH10), 
proinsulin (Alpco #80-PINMS-E01), C-peptide (Alpco #80-CPTMS-E01), glucagon (Mercodia, #10-
1281-01). Measurements were performed on a Spark plate reader (TECAN), and analysed using 
(GraphPad Software Inc., San Diego, CA). 
 
Mathematical modeling 
We used a modified version of the Topp model (Topp et al., 2000) to simulate glucose and insulin 
dynamics (see equations in Fig. 6A). Parameter values for the glucose and insulin equations were 
modified by hand so that the model matched a typical wildtype female low-fat-diet glucose tolerance 
test time series and predicted the observed beta cell mass in these mice. We included an inhibition 
factor, 1/(1 + Sβ I), multiplying the insulin secretion term that accounts for insulin receptor-mediated 
negative feedback on insulin secretion, parametrized by Sβ, β-cell Insr-specific insulin sensitivity. In 
glucose clamp conditions, a simple equation relates Sβ to steady state insulin levels in wildtype and 
mutant mice:  Sβ = (Im 
* - Iwt 
*) / (Im 
*)2 , where Iwt 
* is the steady state insulin level for wild type control 
mice, and Im
* is the equivalent for the βInsrKO mice. We assumed that, at each time point after the first 
one in the glucose-clamp insulin measurements, the blood insulin levels were hovering around steady 
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state and all other parameters and variables were constant (Fig. S5A). We used those steady state 
data points to estimate Sβ for the male and female wild type mice using this equation. 
Glucose tolerance tests were simulated for various Sβ and SP values by calculating the IG system 
steady state values for each Sβ and SP, then using the steady state value as the initial condition for 
insulin, and steady state plus 20 mM as the initial condition for glucose. Fig. 6A shows sample in silico 
glucose tolerance tests for various values of Sβ, with SP fixed at 70. The glucose tolerance area under 
the glucose curve (AUGC) was then calculated for each set of Sβ and SP, generating a numerical map 
from Sβ and SP to AUGC. From the glucose tolerance tests in wildtype and mutant male mice and 
wildtype and mutant female mice, we calculated the experimental AUGC values at 4, 9, 21 and 39 
weeks. Using the computed AUGC map and the Sβ values calculated from the glucose-clamp data, we 
estimated the SP value that would give the experimental AUGC (Fig. S5C)  
 
Statistics 
Data are presented as mean +/- SEM, with individual data points, unless otherwise indicated. T-
tests were performed when only 2 groups were compared at a single timepoint. One-way ANOVA was 
applied when three groups were compared at a single timepoint. Mixed effects model statistics were 
used for statistical analysis of GTT, ITT, GSIS experiments. Specifically, a fitted mixed model (Prism 
8, Graph Pad), which allows for missing measurements and un-even group sizes, was applied when 2 
or more groups were compared at multiple time points (e.g. 4h fasted blood glucose, insulin, 
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Figure 1. An animal model to examine the role of abundant Insr in β-cells. (A) INSR protein 
(isoform A and B) and INSR mRNA expression across human tissues. Left 3 columns show INSR 
isoform A and B protein abundance expressed as normalized median intensity (NMI; 
www.proteomicsdb.org). Right 3 columns show total INSR mRNA expression in the same tissues 
(where available) extracted from 3 databases. Left to right, mRNA data from human proteome atlas 
(HPA) and genotype tissue expression project (GTEX) are shown in reads per kilobase million 
(RPKM). Data from the FAMTOMS database is shown as transcripts per kilobase million (TMP). (B) 
Human insulin receptor expression in islet cell subtypes extracted from an integrated dataset of 
human single cell RNA seq data (see Methods). Normalized expression levels are shown in UMAP 
space (top) and as a ridge plot on a log scale (bottom). The height of the ridge indicates the frequency 
of cells at a given expression level. (C) Breeding strategy for generating β-cell specific βInsrKO, 
(βInsrHET), and littermate control Cre-only mice. (D) Robust Cre recombination verified by imaging the 
nTnG reporter allele in an isolated islet from an Ins1Cre/wt;nTnG mouse. (E) Western blot of Insr protein 
in islets isolated from βInsrKO, (βInsrHET), and littermate control Cre-only mice. (F) Insr mRNA 
expression across tissues in 16 week-old LFD-fed control, βInsrHET, and βInsrKO mice assessed by 
qPCR (n=3 in females, n=5-6 in males). 
 
Figure 2. Transcriptomic analysis of purified Insr deficient β-cells. (A) Differentially expressed 
genes between FACS purified GFP-positive β-cells from βInsrKO and control mice are shown overlaid 
on a diagram of their predicted functional roles. See Figure S1 for full gene names. 
 
Figure 3. β-Cells lacking Insr have increased action potential and calcium oscillation 
frequencies. (A,B) Representative image and quantification of Slc2a2 (Glut2) in islet from sectioned 
pancreas from a LFD-fed 13 week old female control and βInsrKO mice. Unpaired t-test. (C) Oxygen 
consumption rate data of dispersed islets from 16 week-old chow-fed control, βInsrHET, and βInsrKO 
mice. Data analyzed with mixed effects model from independent islet cultures from 3 male and 1 
female mice. (D) Representative traces of action potential firing in β-cells from 16 week-old chow-fed 
mice. Glucose changed as indicated. (E-G) Quantification of action potential properties and reversal 
potentia during the 10mM glucose phase in patch clamped dispersed β-cells. Data analyzed using un-
paired t-test (n=16-17 cells, from 3 mice per group). (H) β-Cell exocytosis measured as increased 
membrane capacitance normalized to initial cell size (fF/pF) over a series of ten 500 ms membrane 
depolarizations from -70 to 0 mV (n= control 32 cells, 29 βInsrKO cells, from 3 pairs of mice). (I) Ca2+ 
dynamics measured in dispersed islet cells (Fura-2 340/380 ratio) treated as indicated from a baseline 
of 3 mM glucose). (J) Quantification of glucose induced Ca2+ oscillation number (n=3523 cells). 
ANOVA with correction for multiple comparisons using Tukey’s method. Additional quantification of 
these traces can be found in Fig. S2.  
 
Figure 4. Insr knockout increases glucose-stimulated insulin secretion in vitro and in vivo. 
(A,B) Perifused islets isolated from 16 week old chow-fed control, βInsrHET, βInsrKO (A) female 
(n=3,3,5), and (B) male (n=6,5,5) mice were exposed to 20 mM glucose (20G), 10 mM glucose (10G), 
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and 30 mM KCL (KCL) from a baseline of 3 mM glucose. Data analyzed using repeated measures 
mixed effects model. Quantification of area under the curve (AUC) is shown for 1st phase and 2nd 
phase during 15 mM glucose stimulation, total response during 10 mM glucose stimulation, and during 
30mM KCL stimulation. AUC’s were analyzed with 1-way ANOVA analysis. (C,F) Glucose infusion 
rates, (D,G) plasma glucose levels, and (E,H) plasma insulin levels during 2 h hyperglycemic clamps 
in awake of LFD-fed 10 week old LFD-fed control and βInsrKO female (n=14, 15) and male (n=4, 4) 
mice. Data were analyzed using repeated measures mixed effects model. (I,J) Insulin levels (% basal 
insulin) following a single glucose injection (2g glucose/kg body mass,i.p) of 11 week old LFD-fed 
control, βInsrHET, βInsrKO  female (n=33,34,23) and male (n=22,29,17) mice. Data were analyzed using 
repeated measures mixed effects model. (K,L) 30min islet protein synthesis measured by S35 labeling 
in islets isolated from control, βInsrHET, βInsrKO  female (n=7,5,6) and male (n=5,4,3) mice. Data were 
analyzed by 1-way ANOVA. (M,N) Insulin content of 10 islets isolated from control, βInsrHET, βInsrKO  
female (n=4,3,5) and male (n=5,4,5) mice. Data were analyzed by 1-way ANOVA.  
 
Figure 5. Islet cell proliferation and relative area in mice lacking β-cell Insr. (A) A representative 
image showing islet architecture via staining for insulin, glucagon and DNA. (B-E) β-Cell area shown 
as a percentage of total pancreatic area. Data were analyzed by 1-way ANOVA analyses. (F-S) 4-day 
in vivo glucose infusion in female (n=5 control, 4 βInsrKO ) and male (n=6 control, 8 βInsrKO) mice. 
(F,M) Tail blood glucose and (G,N) insulin data were analyzed using repeated measures mixed effects 
model. (H,O) 4 day average plasma insulin data were analyzed by an unpaired t-test. (I,P) Plasma 
glucagon (tail blood) data were analyzed using repeated measures mixed effects model. (J,Q) 4 day 
average plasma insulin data were analyzed by an unpaired t-test. (K,R) Representative single channel 
and merge images showing islets stained for insulin, glucagon, BrdU and DNA from LFD-fed female 
and male controls and female βInsrKO and male βInsrKO mice following 4day glucose infusion. (L,S) 
Quantification of BrdU+ insulin+ cells and . BrdU+ glucagon+ cells. Data were analyzed by an 
unpaired t-tests. (T) Representative western blot image and quantification of islet lysate from male 
Insrwt/wt;Ins1cre/wt;nTnG (black bar, n=3), Insrf/wt;Ins1cre/wt;nTnG (light blue bar, n=3), Insrf/f;Ins1cre/wt;nTnG 
(dark blue bar, n=3) mice treated with 3 mM or 20 mM glucose. Data were analyzed by 1-way ANOVA.  
 
Figure 6. Glucose tolerance at multiple ages in β-cell specific Insr knockout mice fed 2 different 
diets. (A) modified version of the Topp model. (B, C) Simulations of the effects of reduced β-cell 
insulin sensitivity on glucose stimulated insulin release and glucose tolerance. (D, E) Relationship 
between the contributes of peripheral insulin sensitivity and β-cell insulin sensitivity to the glucose 
AUC and insulin AUC in the in silico glucose tolerance tests. (F) Glucose tolerance tests of control, 
βInsrHET, βInsrKO  LFD-fed female (n4week=16,16,14; n9week=23,25,17; n21week=12,15,12; n39week=8,12,10) 
and male (n4week=10,18,5; n9week=17,30,11; n21week=8,14,8; n39week=9,7,13) as well as HFD-fed female 
(n9week=17,17,14; n21week=12,14,12 n39week=14,16,10; n54week=10,13,11) and male (n9week=7,16,9; 
n21week=7,16,8; n39week=8,14,8; n54week=6,11,7) mice. (All mice received a glucose bolus of 2g 
glucose/kg body mass (i.p) except older HFD-fed males, which received only 2g glucose/kg body 
mass (i.p). *p-values are italicized when βInsrKO   was compared to controls, p-values are underlined 
when βInsrHET  was compared to controls. (G). The glucose tolerance of Chow-fed Insrwt/wt;MIPCre-
ERTM;YFP+/wt (n=7) and Insrf/f;MIPCre-ERTM;YFP+/wt (n=17) mice were examined at 4, 8, 16 and 20 weeks 
after tamoxifen injection (8 weeks of age upon tamoxifen injection (3 x 200 mg/kg over a 1-week 
period). Data were analysed using repeated measures mixed effects models.  
 
Figure 7. Effects of β-cell specific Insr deletion fasting glucose, body weight and organ weight. 
(A-D) Plasma glucose concentration after a 4-h fast in control, βInsrHET, and βInsrKO mice at multiple 
ages in both LFD and HFD. (E-H) Longitudinally tracked body weight in control, βInsrHET, and βInsrKO 
mice at multiple ages in both LFD and HFD. (I,J) Weights, as a percentage of the whole body, of 
inguinal adipose tissue, gonadal adipose tissue, liver, brown adipose tissue and skeletal muscle. Data 
were analysed using repeated measures mixed effects models. (K) Representative immunoblot of Insr 
(n = 4). 
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Tissue INSR-A (NMI) INSR-B (NMI) INSR (RPKM) INSR (RPKM) INSR (TPM)
placenta 4.58 4.59 5.08 115
pancreatic islet 4.53 4.54
pancreas 4.53 4.52 6.18 30 273
adrenal gland 4.37 4.36 10.1 13.5
spleen 4.35 3.17 15.9 40.2 212
ovary 4.11 4.10 14.1 32.1 108
testis 4.05 4.05 3.18 5.4 41
brain 4.03 4.02 4.93 31
colon 3.93 3.92 8.79 10.3 83
liver 3.82 3.83 9.21 12.7 118
uterus/vagina 3.77 3.76 7.2 68
salivary gland 3.72 4.12 3.2 12.3 62
urinary bladder 3.67 3.67 5 10.5 51
kidney 3.57 3.62 16.5 9.4 57
prostate gland 3.49 3.49 5.24 13 53
prefrontal cortex 3.44 3.43 4.2
gut/small intestine 3.33 3.33 5.34 9.8 96
lung 3.30 3.29 3.96 5.5 22
stomach 3.29 3.28 4.9 8.3
breast 3.27 3.26 10.4 44
heart 3.23 3.23 7.62 9.5 55
adipocyte 3.21 3.21 7.66 9.1 62
spinal cord 3.18 2.23
skin 2.24 3.72 3.35 8.1
A
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p < 0.01 





























































.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted October 15, 2020. ; https://doi.org/10.1101/2020.10.15.338160doi: bioRxiv preprint 































































































































































































































































































































































































































































.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted October 15, 2020. ; https://doi.org/10.1101/2020.10.15.338160doi: bioRxiv preprint 


























   
 
         















































































































































































   
 
         








































































































F G H I J












































Glucagon BrdU DNA Glucagon BrdU DNA
Insulin DNABrdU Insulin DNABrdUR











































































3   20       3   20       3   20  
bInsrKOControl
.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted October 15, 2020. ; https://doi.org/10.1101/2020.10.15.338160doi: bioRxiv preprint 










p= 0.04 p= 0.04


























0 30 60 90 1200 30 60 90 120
0 30 60 90 120
4 weeks 9 weeks 21 weeks 39 weeks
0 30 60 90 120
 
0 30 60 90 120
 









9 weeks 21 weeks 39 weeks 54 weeks
4 weeks 9 weeks 21 weeks 39 weeks









0 30 60 90 120
 
p  







0 30 60 90 120 0 30 60 90 120












0 30 60 90 120









1 g/kg1 g/kg1 g/kg
900 30 60 120
  
    
12 weeks of age / 4 w post Tmx 16 weeks of age / 8 w post Tmx
900 30 60 120
  
    
24 weeks of age / 16 w post Tmx
900 30 60 120
  
    
p=0.05
28 weeks of age / 20 w post Tmx
Insrf/f;MIPCre-ERTM;YFP+/wt
Insrwt/wt;MIPCre-ERTM;YFP+/wtG








































































Sβ = 0 (e.g. βInsrKO ) 
Sβ = 4 (e.g. wildtype) CA
.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted October 15, 2020. ; https://doi.org/10.1101/2020.10.15.338160doi: bioRxiv preprint 
p=0.09
p=0.006





































































































































































































































































.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted October 15, 2020. ; https://doi.org/10.1101/2020.10.15.338160doi: bioRxiv preprint 
C
A 104












Predicted transcription factor network
PPI network
Insulin signaling PPI subnetwork
Increased
Gene Name CPM WT sem CPM HT sem CPM KO sem Glycemic Obesity Function (Uniprot summary)
Jak2 14 1 24 6 26 1 Jak-Stat signalling from GH, prolactin, leptin
Dusp26 13 3 27 4 41 3 BMI Inactivates MAPK1/MAPK3, p38 MAPK
Tmem123 28 1 37 6 41 2 BMI oncocytic cell death
Prpf38a 11 4 11 2 27 1 pre-mRNA splicing
Tm4sf4 378 28 475 50 529 17 cell proliferation
Utp3 11 3 15 4 28 2 T2D gene silencing, chromatin
Rnf138rt1 6 2 16 3 19 2 ring finger protein 139
Atp6ap2 334 23 377 36 475 20 activates ERK1/2, RAS system
Wipf2 16 2 25 3 27 2 PDGFB signalling
Rela 18 3 18 3 33 2 aT2D whr aBMI NFkB signalling
Ogfr 17 1 23 2 31 2 BMI Met-enkephalin signalling, growth regulation
Cers6 18 1 30 3 32 2 rGlucose sphingolipid synthesis
Rnf6 29 6 44 5 55 3 T2D E3 ubiquitin ligase, LIMK1 turnover
Ankrd28 5 1 12 2 18 2 BMI PP6-mediated dephosphorylation of NFKBIE
Slc35b3 10 3 17 3 34 4 sulfation
1110059G10Rik 9 3 15 2 19 1
Tbce 23 3 35 2 48 5 T2D BMI tubulin folding
Morf4l1 265 7 289 20 340 15 aBMI NuA4 histone acetyltransferase, mSin3A complex
Phf6 8 1 15 5 17 2 transcriptional regulation
Csnk2a2 16 2 26 2 33 4 apoptosis, cell cycle, transcription, viral infection
Ptges3l 3 1 4 1 6 1 whr aBMI prostaglandin E synthase 2 like
Cnot6l 111 6 138 13 143 6 WHR transcriptional regulation
Thap3 10 1 15 2 15 1 BMI transcriptional regulation
Ptbp3 134 10 186 21 207 15 pre-mRNA alternative splicing
Gm10182 3 0 8 2 6 1
Myd88 15 0 12 2 20 1 TLR signalling
Kras 55 7 84 9 103 10 GTPase, insulin and growth factor signalling
Cr1l 46 3 41 5 63 3 whr aBMI complement component
Ppp1r7 21 3 28 2 38 4 phosphatase, PP1; ERK signalling
Acadl 21 2 26 5 36 3 beta-oxidation
Prpf31 11 2 20 3 22 2 pre-mRNA splicing
Human GWAS
Decreased
Gene Name CPM WT sem CPM HT sem CPM KO sem Glycemic Obesity Function (Uniprot summary)
Prnp 739 11.5 727 39.6 660 9.0 lycosylphosphatidylinositol-anchored glycoprotein
Vps8 90 5.8 67 11.7 53 4.7 vesicle transport, endocytosis
Gramd1a 69 5.4 51 6.2 42 3.0 cholesterol transport
Ddx31 44 1.4 44 7.6 24 3.2 ATP-dependent RNA helicase
Crybb3 284 34.3 197 42.3 116 20.7 structual component of vertebrate eye lens
Adamts2 5 0.6 4 0.7 3 0.3 whr aBMI type I and II collagen propeptide cleavage
Hdc 5 0.6 2 0.5 2 0.4 histamine biosynthesis
Ttll12 12 1.7 7 1.6 4 1.0 HbA1c post-translational tubulin modifications
Pygo2 35 2.3 33 3.2 27 0.9 whr aBMI Wnt signalling
C2 6 1.0 2 0.8 2 0.4 T1D, T2D whr aBMI complement factor
Brsk2 21 2.9 12 2.3 10 1.2 BMI insulin secretion
Tmem242 35 5.8 21 2.7 15 1.8 transmembrane protein 242
Atf6b 25 1.8 18 2.7 18 0.8 T1D, T2D BMI ER stress signalling
Apobec1 60 2.5 51 6.8 40 3.8 postranscriptional editing, DNA methylation
Slc25a42 30 5.0 22 2.2 13 2.2 mitochondrial CoA transporter
Fam83g 28 4.5 20 6.3 14 1.5
Gm3052 17 2.3 9 2.2 8 1.4
Mettl8 10 2.5 5 1.5 2 0.6 whr aBMI histone methyltransferase
Mapk8ip3 67 7.9 46 6.3 36 4.6 JNK and MAPK signalling, vesible traffic
Rbpms 72 5.2 64 8.4 50 3.8 TGFB1/SMAD signalling
Hars2 25 1.7 16 2.4 12 2.5 class II aminoacyl-tRNA synthetase
Rab3a 113 3.5 84 9.0 84 5.7 whr aBMI insulin secretion
Hmgn1 92 6.3 77 3.5 66 4.3 BMI histone modification
Bmpr2 24 1.3 18 3.7 13 2.0 BMI BMP7, BMP2, BMP4 signalling
Rel 11 2.3 6 1.4 4 0.9 NFkB signalling
L3mbtl2 22 5.0 12 2.5 7 1.4 BMI chomatin modification, polycomb group
Sympk 29 4.9 20 3.0 14 1.6 T2D BMI pre-mRNA polyadenylation, tight junctions
Nanos1 5 1.3 3 0.5 2 0.2 translational repressor
Polr2a 100 9.6 71 7.2 69 4.5 protein synthesis
Dnaic1 7 1.5 4 0.9 2 0.8 dynein complex in respiratory cilia
Camk2b 166 8.5 155 8.5 132 6.2 T2D calcium signalling
Hnf4g 6 1.8 3 1.0 1 0.4 BMI transcription factor
Pdzd11 57 6.9 39 5.4 34 3.4 plasma membrane calcium ATPase-interacting
Rabl6 73 1.0 71 7.9 52 4.7 Proliferation, interactors CDKN2A




Fig. S1. RNA sequencing analysis of Insr-deficient purified beta-cells. (A) FACS plot example of sorted cells. (B)
Significantly different Reactome Pathways. (C) List of most significantly upregulated or downregulated individual genes.
Data are shown for control control, bInsrHET, and bInsrKO (n=4-7). (D) Protein-protein interaction networks constructed
around differentially expressed genes. (E) Transcription factors predicted to mediated differential gene expression.
Individual transcription factors that were increase (blue) or decreased (red) are highlighted.
Significantly Altered Reactome Pathways Set Size % of Set p value q value
DEx/H-box helicases activate type I IFN and inflammatory cytokines production 13 15 0.001 0.048
p75NTR signals via NF-kB 16 12 0.002 0.048
Activation of NF-kappaB in B cells 18 11 0.002 0.048
CD209 (DC-SIGN) signaling 19 10 0.002 0.048
Downstream signaling events of B Cell Receptor (BCR) 30 10 0.000 0.020
RIP-mediated NFkB activation via ZBP1 23 8 0.003 0.048
RAF activation 25 8 0.004 0.048
TRAF6 mediated NF-kB activation 26 7 0.004 0.048
ZBP1(DAI) mediated induction of type I IFNs 27 7 0.004 0.048
TAK1 activates NFkB by phosphorylation and activation of IKKs complex 32 6 0.006 0.054
Signaling by RAS mutants 36 5 0.008 0.061
Signaling by moderate kinase activity BRAF mutants 38 5 0.008 0.061
Paradoxical activation of RAF signaling by kinase inactive BRAF 38 5 0.008 0.061
Transport of vitamins, nucleosides, and related molecules 39 5 0.009 0.061
mRNA Splicing - Major Pathway 178 2 0.004 0.048
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Fig. S2. Additional quantification of dynamic Ca2+ responses. Responses to glucose or KCl were defined as the
median high glucose (15mM) or KCl (30mM) signal above baseline glucose (3mM), respectively, and normalized to the
maximum response to KCl above baseline. High glucose-stimulated Ca2+ oscillations, Ca2+ oscillation in low glucose,
and KCl-stimulated Ca2+ oscillation were defined as the median absolute deviation (MAD) during the high glucose, low
glucose or KCl exposures, respectively, normalized to the maximum response to KCl above baseline.
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Fig. S3. Fasting insulin, glucagon, and glucose levels. (A-D) Circulating plasma insulin levels after a 4-hour fast,
(E-H) or a 16-hour fast; (I-K) plasma glucagon levels after a 16-hour fast (L-O) plasma glucose concentration after a
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Fig. S4. Fasting proinsulin and C-peptide. (A-D) Circulating plasma proinsulin and C-peptide levels after a 4-hour
fast, and their associated ratios in control, bInsrHET, and bInsrKO mice at multiple ages. Statistical analyses were done
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Fig. S5 Mathematical modeling of glucose tolerance. (A,B) Relationship between insulin and glucose during the
hyperglycemia clamps over time in female and male mice. Data from the clamp studies were used to define a beta-cell
insulin sensitivity term that was included in a modified Topp model (see main text). (C) Modelled effects of peripheral
insulin sensitivity and beta-cell insulin sensitivity on glucose AUC (topographical lines). Female response is shown in
the pink shadow and male response in the blue shadow. The experimental effects of the knockout are shown as the
single data point with SEM bars. (D) Model-assessed change in peripheral insulin sensitivity with age, using
experimental data. (E) Effects of HFD at 9 weeks, where comparable glucose bolus was given.
MaleFemale
D
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Fig. S6. Insulin tolerance tests. (A-D) Insulin tolerance tests after a 6 hour fast in control, bInsrHET and bInsrKO mice fed
LFD or HFD at multiple ages (n=5-26). Statistical analyses were done with repeated measures 2-way ANOVA. Doses
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Fig. S7. Fasting insulin, proinsulin, C-peptide and glucagon in control mice. (A-D) Circulating plasma insulin,
proinsulin and C-peptide levels after a 4-hour fast, and their associated ratios as well as 16-hour fasted insulin,
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Fig. S9. Glucose tolerance and fasting glucose comparison in controls. (A-D) Glucose tolerance tests after a 6
hour fast in female and male of Insrwt/wt;Ins1Cre/wt;nTnG+/- (black) and Insrwt/wt;Ins1wt/wt;nTnG+/- (grey) fed LFD or HFD at
multiple ages (n=5-30). Statistical analyses were done with repeated measures 2-way ANOVA. (E-H) Blood glucose
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Fig. S9. Insulin tolerance tests in control mice. (A-D) Insulin tolerance after a 6 hour fast in female and male of
Insrwt/wt;Ins1Cre/wt;nTnG+/- (black) and Insrwt/wt;Ins1wt/wt;nTnG+/- (grey) fed LFD or HFD at multiple ages (n=5-30).
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Fig. S10. Body weight in control mice. (A-D) Body weight in female and male of Insrwt/wt;Ins1Cre/wt;nTnG+/- (black) and
Insrwt/wt;Ins1wt/wt;nTnG+/- (grey) fed LFD or HFD at multiple ages. Statistical analysis with mixed effect model.
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